Pharmline was founded in 1986 by Mr. John Witterschein 

September 1986 become exclusive agent for Kowa Company Ltd Japan and begin sales of Coenzyme Q 10 

May 1987 begin working with JC Martens (which became Pronova, then Epax)

August 1987 begin in-house micronization services for soft gelatin manufacturers

November 1989 begin construction of blending & granulation facility in Florida, NY

January 1990 move from New Jersey to Florida, NY

February 1991 published first validated method in USA for determination of 10-HDA in Royal Jelly products.

March 1992 completed expansion of production area and installed Plant Extraction Unit

August 1993 introduced PhytoActives (trademarked line) of standardized plant extracts

September 1995 began sales of Industrial Organica patented line of carotenoids

May 1995 opened Pharmline office in Nanjing, China

January 1996 introduced Rhodiola Rosea Extract to USA market

March 1997 published 30 validated methods for analysis of standardized plant extracts

February 2000 began construction of dedicated Fluid Bed Granulation facility.

March 2001 completed renovation of original production facility, replacing all blending, drying and milling equipment.

February 2000 became first U.S. ingredient supplier to provide in-house screening of raw materials for gamma irradiation

March 2003 received NNFA GMP Certification

May 2007 received NPA (successor to NNFA) GMP re-certification

In July 2007 GBI completed the acquisition of 85% of Pharmline.
The acquisition is based on the strong synergies exist between the companies